(Q38386336)

2 September 2017

Dengue human infection models to advance dengue vaccine development (English)

1 reference

2 September 2017

0 references

2

Stephen S Whitehead

1 reference

2 September 2017

3

Anna P Durbin

1 reference

2 September 2017

Christian P Larsen

1

1 reference

PubMed ID

26424605

2 September 2017

language of work or name

English

0 references

publication date

27 September 2015

1 reference

2 September 2017

8

1 reference

inferred from page(s)

published in

Vaccine

1 reference

2 September 2017

33

1 reference

2 September 2017

50

1 reference

2 September 2017

7075-7082

1 reference

The global distribution and burden of dengue

2 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Dengue and dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Research on dengue during World War II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

A prospective study of dengue infections in Bangkok

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Reduced risk of disease during postsecondary dengue virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Further Experiments in the Etiology of Dengue Fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Evaluation of dengue virus strains for human challenge studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Sonographic findings of healthy volunteers infected with dengue virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

Evidence That Maternal Dengue Antibodies Are Important in the Development of Dengue Hemorrhagic Fever in Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

7 January 2021

Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

7 January 2021

Dengue Virus Replication Enhancement in Peripheral Blood Leukocytes from Immune Human Beings

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

7 January 2021

Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.052

7 January 2021

10.1016/J.VACCINE.2015.09.052

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

26424605